2020 Dermatology and Allergic Disease Request for Proposals
AKC Canine Health Foundation
2020 Dermatology and Allergic Disease Request for Proposals (RFP)
The AKC Canine Health Foundation supports novel and multi-disciplinary approaches to addressing the health needs of all dogs. We are continuing our commitment to canine health by seeking to fund critical research to diagnose, prevent and/or treat dermatologic and allergic diseases in dogs, including the molecular profiling of canine atopic dermatitis (CAD).
CHF is seeking innovative approaches to canine atopy, with a primary goal of the studies supported by this request to include the identification of novel immune signaling targets involved in pathophysiology of CAD, and to further validate and prioritize a next generation of pharmaceutical or vaccine targets of which agonism or antagonism might improve the lives of dogs with CAD.
Of special interest are applications proposing the molecular profiling (e.g., genomic, proteomic, lipidomic, transcriptomic, microbial populations, microbial metabolites) of diseased vs. normal tissues that can be used as a surrogate to monitor the levels and regulation of cytokines and other immunomodulatory factors involved in initiation or maintenance of a naturally-occurring CAD disease state. The collection and molecular profiling of samples from healthy control and atopic dogs is encouraged to begin to address the following questions:
- What are the key differences in molecular profiles between affected and unaffected skin in dogs with naturally occurring CAD compared to healthy dog skin? Are there molecular and physiologic differences in affected and unaffected skin from the same individual? Can such dysregulation of identified gene circuits be mapped temporally, or as a function of disease initiation and progression?
- What are the molecular determinants of response to treatment with current standard of care for CAD? What are the molecular/physiologic consequences to discontinuing therapy?
- How does the clinical presentation and progression of CAD correlate with the molecular profile of the affected tissue? Are there biomarkers that can be identified and validated that can be used to predict and monitor initiation, progression, or resolution of disease?
- Which targets, when engaged by a drug, are more likely to address and resolve the underlying atopic disease vs. the clinical signs associated with the disease?
- What is the role of microbiome, both directly on the skin (via modulation of immune responses) and via the gut-skin axis with respect to disease initiation, progression, and/or resolution?
Strong collaboration between laboratory researchers and clinician scientists is highly encouraged.
The deadline for online applications is Monday, March 30th, 2020 at 11:59 PM Eastern. Both Acorn ($15,000 maximum including 8% maximum indirect costs) and Oak (over $15,000, and up to $100,000, including 8% maximum indirect costs) grant proposals that can be completed within the budget will be accepted for review.
All work completed under this funding must strictly adhere to the Foundation's Humane Use of Animals Policy. Funding eligibility details can be found .
Questions regarding this RFP should be directed to Andrea Fiumefreddo, CHF Director of Programs & Operations.
Please forward this announcement to other researchers seeking funding in this area of research.
Previously awarded CHF grants and active research in this area can be found here: Dermatology and Allergic Disease
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.